14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -2.043 8 days ( 1.71 % )
Last Price $1.15 1.77 %
High/ Low $1.10 - $1.16 -0.91%
Chg 7 Days -4.17 % $1.20 $1.15
Chg 30 Days -8.00 % $1.25 $1.15
Chg 12 mos -6.50 % $1.23 $1.15
Trend - 3 mos -16.68 % Width: 30.96 %
Trend - 12 mos -1.57 % Width: 412.66 %
Pred. range - 3 mos $0.83 - $1.08 -28.04 % - -5.76 %
Pred. range - 12 mos $0.98 - $5.01 -14.94 % - 336.08 %
Short MA avg 3 mos Sell Sep 27, 2024 - 6 days
Long MA avg 3 mos Sell Sep 12, 2024 - 17 days
Short/Long MA avg 3 mos Sell Sep 19, 2024 - 12 days
Short MA avg 12 mos Sell Sep 13, 2024 - 16 days
Long MA avg 12 mos Sell May 10, 2024 - 102 days
Short/Long MA avg 12 mos Sell Jun 05, 2024 - 85 days
Pivot Short Sell Oct 03, 2024 - 2 days
Bollinger Buy Sep 11, 2024 - 18 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!
ABOUT CYTOMX THERAPEUTICS
CytomX Therapeutics
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme...
GOLDEN STAR
Ticker Change Signal Date
WM
$207.93
0.558% Oct 01
VET
$9.77
7.06% Sep 30
FSK
$19.73
1.57% Sep 30
XOM
$115.82
5.84% Sep 27
HES
$133.61
5.43% Sep 27

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE